Oncolytic viruses / edited by Christine E. Engeland
Introduction to Oncolytic Virotherapy -- Methods for Modification of Therapeutic Viruses -- Tumor Targeting of Oncolytic Adenoviruses using Bispecific Adapter Proteins -- Development of Entry-targeted Oncolytic Measles Viruses -- Insert Stability and In Vivo Testing of MicroRNA-Detargeted Oncolytic Picornaviruses -- Ex vivo Virotherapy with Myxoma Virus to Treat Cancer -- Immunomodulation in Oncolytic Measles Virotherapy -- A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death -- Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation -- Analysis of Immunological Treatment Effects of Virotherapy in Tumor Tissue -- Immunohistochemistry for Tumor-infiltrating Immune Cells after Oncolytic Virotherapy -- Detection of Tumor Antigen-specific T-cell Responses after Oncolytic Vaccination -- Evaluation of Oncolytic Virus Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models -- Delivery of Oncolytic Reovirus by Cell Carriers -- In Vivo Bioimaging for Monitoring Intratumoral Virus Activity -- Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 virus: Using a Bladder Tumour Precision-cut Slice Model System to Assess Viral Efficacy -- Use of Liquid Patient Ascites Fluids as a Pre-clinical Model for Oncolytic Virus Activity -- Generating Primary Models of Human Cancer to Aid in the Development of Clinically-relevant Oncolytic Viruses -- Considerations for Clinical Translation of MG1 Maraba Virus -- Fluorescence in Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-treated Human Brain Tumors -- Mathematical Modeling of Oncolytic Virotherapy.
This book aims to provide a guide for virologists, translational researchers, and clinicians in the field of cancer research by providing reference protocols and methodologies from vector development through clinical translation. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Oncolytic Viruses: Methods and Protocols aims to ensure successful results in the further study of this vital field.
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
New York, NY: Humana ; 2020 |
| Ausgabe: |
1st ed. 2020 |
| Weitere Ausgaben: |
Erscheint auch als Druck-Ausgabe: Oncolytic viruses |
|---|
| Reihe: |
Methods in Molecular Biology - 2058 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Engeland, Christine Elisabeth, 1985- [HerausgeberIn] |
|---|
| Links: |
doi.org [lizenzpflichtig] |
|---|
| ISBN: |
|---|
| Umfang: |
1 Online-Ressource (XI, 329 p. 64 illus., 48 illus. in color) |
|---|
| doi: |
10.1007/978-1-4939-9794-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1678684805 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1678684805 | ||
| 003 | DE-627 | ||
| 005 | 20240413113102.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191010s2020 xxu|||||o 00| ||eng c | ||
| 020 | |a 9781493997947 |9 978-1-4939-9794-7 | ||
| 024 | 7 | |a 10.1007/978-1-4939-9794-7 |2 doi | |
| 035 | |a (DE-627)1678684805 | ||
| 035 | |a (DE-599)KEP047001836 | ||
| 035 | |a (DE-He213)978-1-4939-9794-7 | ||
| 035 | |a (EBP)047001836 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XD-US | ||
| 050 | 0 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 thema | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 245 | 1 | 0 | |a Oncolytic viruses |c edited by Christine E. Engeland |
| 250 | |a 1st ed. 2020 | ||
| 264 | 1 | |a New York, NY |b Humana |c 2020 | |
| 300 | |a 1 Online-Ressource (XI, 329 p. 64 illus., 48 illus. in color) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Methods in Molecular Biology |v 2058 | |
| 490 | 0 | |a Springer eBook Collection | |
| 490 | 0 | |a Springer eBooks |a Springer Protocols | |
| 520 | |a Introduction to Oncolytic Virotherapy -- Methods for Modification of Therapeutic Viruses -- Tumor Targeting of Oncolytic Adenoviruses using Bispecific Adapter Proteins -- Development of Entry-targeted Oncolytic Measles Viruses -- Insert Stability and In Vivo Testing of MicroRNA-Detargeted Oncolytic Picornaviruses -- Ex vivo Virotherapy with Myxoma Virus to Treat Cancer -- Immunomodulation in Oncolytic Measles Virotherapy -- A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death -- Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation -- Analysis of Immunological Treatment Effects of Virotherapy in Tumor Tissue -- Immunohistochemistry for Tumor-infiltrating Immune Cells after Oncolytic Virotherapy -- Detection of Tumor Antigen-specific T-cell Responses after Oncolytic Vaccination -- Evaluation of Oncolytic Virus Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models -- Delivery of Oncolytic Reovirus by Cell Carriers -- In Vivo Bioimaging for Monitoring Intratumoral Virus Activity -- Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 virus: Using a Bladder Tumour Precision-cut Slice Model System to Assess Viral Efficacy -- Use of Liquid Patient Ascites Fluids as a Pre-clinical Model for Oncolytic Virus Activity -- Generating Primary Models of Human Cancer to Aid in the Development of Clinically-relevant Oncolytic Viruses -- Considerations for Clinical Translation of MG1 Maraba Virus -- Fluorescence in Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-treated Human Brain Tumors -- Mathematical Modeling of Oncolytic Virotherapy | ||
| 520 | |a This book aims to provide a guide for virologists, translational researchers, and clinicians in the field of cancer research by providing reference protocols and methodologies from vector development through clinical translation. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Oncolytic Viruses: Methods and Protocols aims to ensure successful results in the further study of this vital field | ||
| 650 | 0 | |a Oncology | |
| 650 | 0 | |a Medical virology | |
| 650 | 0 | |a Cancer Research | |
| 650 | 0 | |a Cancer research | |
| 650 | 0 | |a Virology | |
| 650 | 4 | |a Virus oncolytiques | |
| 650 | 4 | |a Thérapie virale de cancers ; méthodes | |
| 650 | 4 | |a Tumeurs ; thérapie | |
| 650 | 4 | |a Thérapie virale de cancers ; immunologie | |
| 650 | 4 | |a Tumeurs ; Thérapeutique | |
| 650 | 4 | |a Virothérapie oncolytique | |
| 700 | 1 | |a Engeland, Christine Elisabeth |d 1985- |e herausgeberin |0 (DE-588)1025405951 |0 (DE-627)722221193 |0 (DE-576)370314670 |4 edt | |
| 776 | 1 | |z 9781493997930 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Oncolytic viruses |d New York : Humana Press, 2019 |h 1 v. (XI, 329 p.) |w (DE-627)1743359721 |z 9781493997930 |z 1493997939 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 978-1-4939-9793-0 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4939-9794-7 |m X:SPRINGER |x Resolving-System |z lizenzpflichtig |
| 912 | |a ZDB-2-PRO |b 2020 | ||
| 912 | |a ZDB-2-SEB | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a ISIL_DE-84 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a ISIL_DE-8 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a ISIL_DE-3 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a ISIL_DE-21 | ||
| 912 | |a GBV_ILN_2002 | ||
| 912 | |a ISIL_DE-21-123 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a ISIL_DE-93 | ||
| 912 | |a GBV_ILN_2017 | ||
| 912 | |a ISIL_DE-576 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a ISIL_DE-289 | ||
| 951 | |a BO | ||
| 953 | |2 045F |a 614.5999 | ||
| 980 | |2 20 |1 01 |x 0084 |b 4467610715 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |h CATDESC_SPR-EB |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |u CATDESC_SPR-EB |y z |z 25-01-24 | ||
| 980 | |2 24 |1 01 |x 0008 |b 3833958901 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |h OLR-ESPPRO |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Die Weitergabe an Dritte sowie systematisches Downloaden sind untersagt. |y z |z 10-01-21 | ||
| 980 | |2 65 |1 01 |x 0003 |b 3525304323 |c 03 |f --%%-- |d ebook |e --%%-- |j --%%-- |h OLR-ZDB-2-PRO |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Die Weitergabe an Dritte sowie systematisches Downloaden sind untersagt. |y k3o |z 19-10-19 | ||
| 980 | |2 2001 |1 01 |x DE-21 |b 3521420655 |c 00 |f --%%-- |d --%%-- |e --%%-- |j kp |y l01 |z 10-10-19 | ||
| 980 | |2 2002 |1 01 |x DE-21-123 |b 3521335038 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |y l01 |z 10-10-19 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 4208478357 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Campuslizenz |y l01 |z 10-11-22 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 3858556971 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 18-02-21 | ||
| 980 | |2 2015 |1 01 |x DE-93 |b 3521335046 |c 00 |f --%%-- |d --%%-- |e p |j --%%-- |k Campuslizenz |y l01 |z 10-10-19 | ||
| 980 | |2 2017 |1 01 |x DE-576 |b 3521335054 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Besitznachweis BSZ nur für Dateneinspielung, keine echte Lizenz vorhanden |y l01 |z 10-10-19 | ||
| 980 | |2 2021 |1 01 |x DE-289 |b 3567785761 |c 00 |f --%%-- |d --%%-- |e --%%-- |j k |y l01 |z 20-12-19 | ||
| 981 | |2 20 |1 01 |x 0084 |r https://doi.org/10.1007/978-1-4939-9794-7 | ||
| 981 | |2 24 |1 01 |x 0008 |r https://doi.org/10.1007/978-1-4939-9794-7 | ||
| 981 | |2 65 |1 01 |x 0003 |y Volltextzugang Campus |r https://doi.org/10.1007/978-1-4939-9794-7 | ||
| 981 | |2 2001 |1 01 |x DE-21 |r https://doi.org/10.1007/978-1-4939-9794-7 | ||
| 981 | |2 2002 |1 01 |x DE-21-123 |r https://doi.org/10.1007/978-1-4939-9794-7 | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://doi.org/10.1007/978-1-4939-9794-7 | ||
| 981 | |2 2015 |1 01 |x DE-93 |r https://doi.org/10.1007/978-1-4939-9794-7 | ||
| 981 | |2 2021 |1 01 |x DE-289 |r https://doi.org/10.1007/978-1-4939-9794-7 | ||
| 982 | |2 2001 |1 01 |x DE-21 |8 00 |s s |a eBook-Springer-Protocols | ||
| 982 | |2 2002 |1 01 |x DE-21-123 |8 00 |s s |a eBook-Springer-Protocols | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hdpub | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410494721 |a Buch (Monographie) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_1 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_340 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1495014762 |a Engeland, Christine Elisabeth | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)169133667X |a Zentrum für Innere Medizin (Krehl Klinik) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||
| 995 | |2 20 |1 01 |x 0084 |a CATDESC_SPR-EB | ||
| 995 | |2 24 |1 01 |x 0008 |a OLR-ESPPRO | ||
| 995 | |2 65 |1 01 |x 0003 |a OLR-ZDB-2-PRO | ||